Evidence map›Paper›PMID 37386750›Full record

SynthesisResearch synthesis methods2023

Calculating the power of a planned individual participant data meta-analysis of randomised trials to examine a treatment-covariate interaction with a time-to-event outcome.

Richard D Riley, Gary S Collins, Miriam Hattle, Rebecca Whittle, Joie Ensor

Abstract readMeta-Analysis
In one paragraph

Synthesis in Research synthesis methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Richard D RileyInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0001-8699-0735
Gary S CollinsCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0002-2772-2316
Miriam HattleSchool of Medicine, Keele University, Keele, UK.ORCID https://orcid.org/0000-0003-1542-6277
Rebecca WhittleCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0003-1793-0135
Joie EnsorInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0001-7481-0282

Funding

Cancer Research UK 27294Cancer Research UK C49297/A27294Medical Research Council MR/V038168/1
6 · The paper itself

Abstract

Before embarking on an individual participant data meta-analysis (IPDMA) project, researchers should consider the power of their planned IPDMA conditional on the studies promising their IPD and their characteristics. Such power estimates help inform whether the IPDMA project is worth the time and funding investment, before IPD are collected. Here, we suggest how to estimate the power of a planned IPDMA of randomised trials aiming to examine treatment-covariate interactions at the participant-level (i.e., treatment effect modifiers). We focus on a time-to-event (survival) outcome with a binary or continuous covariate, and propose an approximate analytic power calculation that conditions on the actual characteristics of trials, for example, in terms of sample sizes and covariate distributions. The proposed method has five steps: (i) extracting the following aggregate data for each group in each trial-the number of participants and events, the mean and SD for each continuous covariate, and the proportion of participants in each category for each binary covariate; (ii) specifying a minimally important interaction size; (iii) deriving an approximate estimate of Fisher's information matrix for each trial and the corresponding variance of the interaction estimate per trial, based on assuming an exponential survival distribution; (iv) deriving the estimated variance of the summary interaction estimate from the planned IPDMA, under a common-effect assumption, and (v) calculating the power of the IPDMA based on a two-sided Wald test. Stata and R code are provided and a real example provided for illustration. Further evaluation in real examples and simulations is needed.

Indexed as

Sample SizeHumansRandomized Controlled Trials as Topicindividual participant data (IPD) meta-analysispowersample sizetreatment-covariate interactionstreatment effect modifiers

Identifiers

PMID37386750
PMCPMC10947306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.